<DOC>
	<DOCNO>NCT01722266</DOCNO>
	<brief_summary>Hypothesis 1 : Treatment Liraglutide patient type 1 diabetes decrease fast , postprandial overall mean glucose concentration . Aim 1.1 : To compare mean fasting , mean weekly glucose standard deviation weekly blood glucose concentration record continuous glucose monitoring prior follow 6 week 12 week treatment 0.6 , 1.2 1.8 mg liraglutide daily . In addition , time spend glucose concentration &gt; 150 200mg/dl &lt; 70 &lt; 40 mg/dl also compare . Aim 1.2 : To compare postprandial glucose concentration follow test meal 12 week treatment 0.6 , 1.2 1.8 mg liraglutide daily . Glucose concentration measure area curve data obtain meal challenge . Aim 1.3 : To compare HbA1c level ( glycated hemoglobin ) 12 week treatment 0.6 , 1.2 1.8 mg liraglutide daily Hypothesis 2 : Treatment Liraglutide patient type 1 diabetes decrease postprandial glucagon concentration increase postprandial C-peptide concentration . Aim 2.1 : To compare fast postprandial glucagon C-peptide concentration follow test meal 12 week treatment 0.6 , 1.2 1.8 mg liraglutide daily . Hypothesis 3 : Treatment Liraglutide patient type 1 diabetes delay gastric empty . Aim 3.1 : To compare gastric empty measure acetaminophen absorption 12 week treatment 0.6 , 1.2 1.8 mg liraglutide daily .</brief_summary>
	<brief_title>Liraglutide Treatment Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>RESEARCH DESIGN AND METHODS This investigation prospective , randomize , double blind , placebo control study conduct type 1 diabetic . The study conduct Diabetes - Endocrinology Center WNY Millard Fillmore Hospital , affiliate State University New York Buffalo . Study Population : Seventy two patient type 1 diabetes treatment either continuous subcutaneous insulin infusion ( CSII ; also know insulin pump ) multiple ( four ) injection insulin per day include study . They randomize 4 group 18 patient . The patient randomize placebo 0.6 mg , 1.2 mg 1.8 mg liraglutide daily . In view possibility hypoglycemia side effect nausea patient start 0.6 mg liraglutide per day . The dose titrate 1.2 1.8 mg weekly basis . No increase make target dose achieve group . Subjects recruit patient , exist database advertisement . The following insulin preparation use study : insulin detemir , glargine , aspart , glulisine lispro . Subjects continue obtain insulin supply respective pharmacy . STUDY DESIGN : Screening Day ( day -14 ) : - Each patient complete following procedure prior participate study . 1 . Medical History ; 2 . Physical Exam ; 3 . Informed consent . 4 . Baseline lab draw measure Complete blood count , comprehensive metabolic panel , Hba1c lipid profile . All labs drawn fast state morning 10am . Randomization Visit ( day -7 ) Randomization Method : After screen visit , subject meet inclusion exclusion criterion , assign number computerized random number generation program ( Microsoft office - Excel ) randomize receive subcutaneous injection daily either Liraglutide 0.6mg ( 18 subject ) , 1.2 mg ( 18 subject ) , 1.8 mg ( 18 subject ) placebo ( 18 subject ) 12 week . The subject study coordinator blind treatment . The Liraglutide/placebo administer via pen kit ( obtain Novo Nordisk Pharmaceuticals ) . The dose give morning . The sponsor provide study medication blind form . All subject instruct study staff dose administration study medication see Certified Diabetes Educator instruction injection technique . All subject also see register dietitian review carbohydrate count diet make assessment calorie carbohydrate intake . The subject randomize start placebo liraglutide injection till study intervention visit 1 . All subject advise monitor capillary blood glucose fingerstick 2 hour meal wear CGM constantly duration study The subject ask keep diary food intake measure calorie intake . For entire duration study , patient maintain diary record hypoglycemia untoward side effect like nausea , change appetite experience . Patients instruct call Diabetes Center endocrinology fellow directly case problem untoward side effect . They specifically ask call hypoglycemia ( blood sugar &lt; 70 mg/dl ) hyperglycemia ( blood sugar &gt; 250 mg/dl ) one occasion . Study Intervention Visit 1 day 0 : - Subjects come fasting visit . Records blood glucose concentration monitor fingerstick CGM previous 7 day obtain assess glycemic control prior liraglutide treatment . They undergo meal challenge test ( describe ) , Liraglutide placebo injection dose 0.6 mg per day start . No reduction make dose pre-prandial insulin bolus basal insulin A1C great equal 7.5 % . Subjects decrease dose pre-prandial insulin boluses 25 % basal 25 % A1C le equal 7 % . Subjects decrease dose pre-prandial insulin bolus basal insulin 10 % A1C 7 &amp; 7.5 % . This reduction base experience ( see preliminary data ) . Careful adjustment make insulin dose discretion investigator basis glucose data obtain patient . The target blood glucose preprandial 90-120mg/dl 2hour PP &lt; 140mg/dl , without increase incidence blood glucose &lt; 70mg/dl . Patients return center 7 day Study Intervention Visit 2 day 7 : - Blood glucose concentration review . Insulin dose adjust discretion study investigator optimize blood sugar control per target mention day 0 visit . Patients advise increase Liraglutide dose 1.2 mg day whose target dose 1.2 1.8 mg . They return 7 day . Study Intervention Visit 3 day 14 : - Blood glucose concentration review . Insulin dose adjust discretion study investigator optimize blood sugar control per target mention day 0 visit . Patients target dose 1.8 mg advise increase dose others continue previous dose . They return 7 day . Study Intervention Visit 4 day 21 , Visit 5 day 28 : Records blood glucose concentration last 7 day collect . Insulin dose adjust discretion study investigator optimize blood sugar control per target mention day 0 visit . Study Intervention Visit 6 day 42 , Visit 7 day 56 , Visit 8 day 70 : Records blood glucose concentration last 15 day collect . Insulin dose adjust discretion study investigator optimize blood sugar control per target mention day 0 visit . Study Intervention Visit 9 day 84 Subjects come fasting visit . Records blood glucose concentration monitor fingerstick CGM previous 7 day obtain assess glycemic control . They undergo meal challenge test ( describe ) . After visit , subject discharge study . Meal challenge test : - In order ass change induce liraglutide , meal challenge carry prior follow liraglutide ( day 0 day 84 ) . ( 910 Calorie High fat High carbohydrate meal several previous paper ) . Acetaminophen ( 1000 mg body weight &lt; 70 kg 1500 mg body weight &gt; 70 kg ) ingest begin meal , blood level acetaminophen determine interval assessment rate gastric emptying . Bolus Insulin inject immediately meal base insulin carbohydrate ratio correction factor individual subject . Liraglutide inject day 84 ( 45 min prior meal ) . Sequential blood sample obtain 0 , 15 , 30 , 45 , 60 , 90 , 120 , 150 , 180 , 210 , 240 300 min . Samples 15 , 30 , 45 , 90 , 150 210 min 5 ml 0 , 60 , 120 , 180 , 240 300 min 30 ml ( total volume=210 ml ) . Blood collect indwell intravenous canula superficial forearm vein . Data safety monitoring : Timely , accurate , complete reporting analysis safety information obtain clinical trial crucial protection subject investigator . All subject refer liraglutide 's label safety information , provide copy package insert medication . Discussion potential side effect different warn precaution take place time signing informed consent . The following Information box warn package insert regard risk thyroid c-cell tumor discuss detail participate subject `` Liraglutide cause dose-dependent treatment-duration-dependent thyroid C-cell tumor clinically relevant exposure gender rat mice . It unknown whether Liraglutide cause thyroid C-cell tumor , include medullary thyroid carcinoma ( MTC ) , human , human relevance could rule clinical nonclinical study . Liraglutide contraindicate patient personal family history MTC patient Multiple Endocrine Neoplasia syndrome type 2 ( MEN 2 ) . Based finding rodent , monitor serum calcitonin thyroid ultrasound perform clinical trial , may increase number unnecessary thyroid surgery . It unknown whether monitor serum calcitonin thyroid ultrasound mitigate human risk thyroid C-cell tumor . '' In addition , follow FDA text regard risk develop fibrosarcomas discuss participate subject `` In 2-year repeat subcutaneous dose carcinogenicity study liraglutide inject day CD-1 mouse , treatment-related increase fibrosarcomas see dorsal skin subcutis , body surface use drug injection , males 3 mg/kg/day group . These fibrosarcomas attribute high local concentration drug near injection site . The liraglutide concentration clinical formulation ( 6 mg/mL ) 10 time high concentration formulation use administer 3 mg/kg/day liraglutide mouse carcinogenicity study ( 0.6 mg/mL ) '' . All Adverse event ( AEs ) report time visit telephone occur . Those meet definition Serious Adverse Events ( SAE 's ) must report use SAE Form . Medical event occur sign Informed Consent first intake study drug document medical history . Subjects voluntarily report AEs response general , non-directed questioning . For AE volunteer subject , investigator obtain information require complete AE page Case Report Form ( CRF ) , accordance guideline accompany . All AEs , regardless seriousness , severity , presume relationship study therapy , record use medical terminology source document CRF . Whenever possible , diagnose give sign symptom due common etiology ( e.g. , cough , runny nose , sneeze , sore throat , head congestion report `` upper respiratory infection ) . Investigators record CRF opinion concern relationship AE study therapy . All measure require AE management record source document report accord sponsor instruction .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Patients type 1 diabetes mellitus : Fasting cpeptide &lt; 0.1nmol/l insulin therapy 12 month without history diabetic ketoacidosis . 2 . Using continuous glucose monitoring device ( CGM ) regularly measure blood sugar four time daily 3 . HbA1c le 8.5 % . 4 . Well versed carbohydrate count 5 . Age 1875 year 1 . Type 1 diabetes less 12 month ; 2 . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week ; 3 . Hepatic disease ( transaminase &gt; 3 time normal ) cirrhosis ; 4 . Renal impairment ( serum creatinine &gt; 1.5 ) ; 5 . HIV Hepatitis C positive status ; 6 . Participation concurrent clinical trial ; 7 . Any lifethreatening , noncardiac disease ; 8 . Use investigational agent therapeutic regimen within 30 day study . 9. history pancreatitis 10. pregnancy 11. inability give inform consent 12. history gastroparesis 13. history medullary thyroid carcinoma MEN 2 syndrome . 14 . Family history MEN 2 , Family history medullary thyroid cancer , familial medullary thyroid cancer 15 . Women childbearing potential use adequate contraception 16 ) Women pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Liraglutide</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Systolic blood pressure</keyword>
	<keyword>Weight</keyword>
	<keyword>Carbohydrate intake</keyword>
	<keyword>Insulin dose</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Post-prandial glucagon</keyword>
</DOC>